Xenobiotic Pathway Gene Polymorphisms Associated with Gastric Cancer in High Risk Mizo-Mongoloid Population, Northeast India

4026 Background: AVAGAST showed regional bevacizumab (Bev) efficacy difference (RBED), namely, Asian (Asi) patients (pts) with gastric cancer (GC) had no benefit whereas European and Pan-American patients had more benefit from Bev. Recently, germline gene polymorphisms in angiogenesis have been recognized as predictive marker for Bev efficacy. Allele frequency (AF) in gene polymorphisms may vary depending on ethnicity. We tested the hypothesis whether angiogenic pathway gene polymorphisms may have different AF among Asi, Caucasian (Cau), and Hispanic (Hisp) in GC and this disparity may explain RBED. Methods: Three-hundred pts [Japanese (Jap), Cau, and Hisp, 100 from each race] with histopathologically confirmed GC were collected from Japan, USA, Austria, and Italy between 1991 and 2011. These pts were divided into 2 groups as training set (n=50) and validation set (n=50) in each race. Seven functional gene polymorphisms previously reported as predictive marker were selected. All samples were analyzed using PCR-based direct DNA- sequencing. Fisher's exact test was used to compare the distribution of AF among races. Results: Significant disparate distributions in favorable AF for Bev were shown among races in Table. Jap GC pts had significant lower AF of 5 predictive gene polymorphisms in training set, and among these 5, three predictive gene polymorphisms were also validated. Conclusions: Our preliminary results showed significant disparate AF distributions in predictive gene polymorphisms for Bev, and these disparities may explain RBED in AVAGAST. Further investigation is warranted to elucidate RBED. [Table: see text]

Download Full-text

Mitochondrial complex I and V gene polymorphisms in type II diabetes mellitus among high risk Mizo-Mongoloid population, Northeast India

Genes and Environment ◽

10.1186/s41021-016-0034-z ◽

2016 ◽

Vol 38 (1) ◽

Cited By ~ 2

Author(s):

Freda Lalrohlui ◽

Sunaina Thapa ◽

Souvik Ghatak ◽

John Zohmingthanga ◽

Nachimuthu Senthil Kumar

Keyword(s):

Type Ii Diabetes ◽

Complex I ◽

Gene Polymorphisms ◽

Type Ii Diabetes Mellitus ◽

Northeast India ◽

Mitochondrial Complex I ◽

Type Ii ◽

Mitochondrial Complex ◽

V Gene ◽

Mongoloid Population

Download Full-text

Interaction of Tobacco Smoking and Chewing with Angiotensin Converting Enzyme (Insertion/Deletion) Gene Polymorphisms and Risk of Lung Cancer in a High Risk Area from Northeast India

Asian Pacific Journal of Cancer Prevention ◽

10.7314/apjcp.2014.15.24.10691 ◽

2015 ◽

Vol 15 (24) ◽

pp. 10691-10695 ◽

Cited By ~ 3

Author(s):

Rup Kumar Phukan ◽

Prasanta Kumar Borah ◽

Bhaskar Jyoti Saikia ◽

Mandakini Das ◽

Gaganpreet Singh Sekhon ◽

...

Keyword(s):

Lung Cancer ◽

High Risk ◽

Angiotensin Converting Enzyme ◽

Tobacco Smoking ◽

Gene Polymorphisms ◽

Northeast India ◽

Converting Enzyme ◽

Risk Area ◽

High Risk Area

Download Full-text

Relevance of PTGS1 and PTGS2 gene polymorphisms to gastric cancer risk and phenotype in Caucasians.

10.26226/morressier.59a6b345d462b80290b54651 ◽

2017 ◽

Author(s):

María Asunción García-González

Keyword(s):

Gastric Cancer ◽

Cancer Risk ◽

Gene Polymorphisms ◽

Gastric Cancer Risk

Download Full-text

Accuracy of upper endoscopies with random biopsies to identify patients with gastric premalignant lesions who can safely be exempt from surveillance

Gastric Cancer ◽

10.1007/s10120-020-01149-2 ◽

2021 ◽

Vol 24 (3) ◽

pp. 680-690

Author(s):

Michiel C. Mommersteeg ◽

Stella A. V. Nieuwenburg ◽

Wouter J. den Hollander ◽

Lisanne Holster ◽

Caroline M. den Hoed ◽

...

Keyword(s):

Gastric Cancer ◽

High Risk ◽

Low Risk ◽

Premalignant Lesions ◽

High Risk Patients ◽

European Guidelines ◽

Progression Of Disease ◽

Risk Patients ◽

Progression Risk

Abstract Introduction Guidelines recommend endoscopy with biopsies to stratify patients with gastric premalignant lesions (GPL) to high and low progression risk. High-risk patients are recommended to undergo surveillance. We aimed to assess the accuracy of guideline recommendations to identify low-risk patients, who can safely be discharged from surveillance. Methods This study includes patients with GPL. Patients underwent at least two endoscopies with an interval of 1–6 years. Patients were defined ‘low risk’ if they fulfilled requirements for discharge, and ‘high risk’ if they fulfilled requirements for surveillance, according to European guidelines (MAPS-2012, updated MAPS-2019, BSG). Patients defined ‘low risk’ with progression of disease during follow-up (FU) were considered ‘misclassified’ as low risk. Results 334 patients (median age 60 years IQR11; 48.7% male) were included and followed for a median of 48 months. At baseline, 181/334 (54%) patients were defined low risk. Of these, 32.6% were ‘misclassified’, showing progression of disease during FU. If MAPS-2019 were followed, 169/334 (51%) patients were defined low risk, of which 32.5% were ‘misclassified’. If BSG were followed, 174/334 (51%) patients were defined low risk, of which 32.2% were ‘misclassified’. Seven patients developed gastric cancer (GC) or dysplasia, four patients were ‘misclassified’ based on MAPS-2012 and three on MAPS-2019 and BSG. By performing one additional endoscopy 72.9% (95% CI 62.4–83.3) of high-risk patients and all patients who developed GC or dysplasia were identified. Conclusion One-third of patients that would have been discharged from GC surveillance, appeared to be ‘misclassified’ as low risk. One additional endoscopy will reduce this risk by 70%.

Download Full-text